Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
This patent grant is significant as it strengthens Greenland Mines' position in the emerging field of gene therapy for neurodegenerative conditions. The Klotho protein has been linked to cognitive function and longevity, and the s-KL splice variant is believed to play a key role in neuroprotection. By securing patent protection in Canada, a key market for pharmaceutical innovation, the company ensures exclusive rights to develop and commercialize therapies using this technology in the country.
The broader intellectual property portfolio now includes patents in the United States, China, Europe and Canada, providing a robust foundation for the company's biotech division. This division is part of Greenland Mines' dual operating strategy, which also includes mining operations focused on rare earth elements and precious metals in Greenland. The company's biotech efforts are centered on advancing KLTO-202, its primary candidate for ALS, which has entered GMP manufacturing in preparation for regulatory interactions. KLTO-101, aimed at other neurodegenerative indications, is slated for process development in 2026.
The news underscores the potential of gene therapies to address unmet medical needs in neurodegenerative diseases, which affect millions worldwide. For Greenland Mines, the patent expansion not only protects its intellectual property but also enhances its attractiveness to potential partners and investors. The company's ability to secure patents across multiple jurisdictions demonstrates the strength and novelty of its technology, which could pave the way for future clinical trials and eventual commercialization.
To view the full press release, visit https://ibn.fm/x2pHA.
